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Abstract 
 
Background: The emergence of antimicrobial resistance (AMR) is a global concern and a growing 
health crisis. Additionally, evidence has shown that non-compliance to treatment guidelines, 
especially in the management of communicable diseases such as sexually transmitted infections 
(STIs), has the potential of further enhancing AMR rates. Data on the extent of these challenges in 
Primary Health Care (PHC) facilities in correctional centres in South Africa (SA) is limited. Hence this 
study was conducted to determine the level of compliance with the 2008 PHC Standard Treatment 
Guidelines and Essential Medicines List (PHC STGs/EML) in the management of STIs, and to identify 
potential factors contributing to the compliance and non-compliance to guide future strategies. 
Method: An investigational descriptive study, including retrospective and prospective data, was 
conducted over an eight month period. Results: Male urethritis syndrome, lower abdominal pain and 
genital ulcer syndrome were the three most common STIs. Doxycycline, ciprofloxacin and 
metronidazole were prescribed for most of the STIs. Overall compliance to the 2008 PHC STGs/EML 
was low for all STIs. Conclusion: The study highlights the need to implement antimicrobial 
stewardship programmes, including educational activities, to promote the rational use of 
antimicrobials and monitor their use in PHCs in SA. 
 
1. Introduction  
 
Globally, sexually transmitted infections (STIs) are among the most common acute conditions with 
significant public health concerns [1, 2]. The World Health Organization (WHO) [3] estimated that 291 
million women are infected with the human papillomavirus (HPV).  The current annual incidence of 
STIs in Africa is 92.6 million, including 8.3 million, 21.1 million, 3.4 million and 59.7 million cases 
respectively for Chlamydia trachomatis, Neisseria gonorrhoeae, Treponema pallidum and 
Trichomonas vaginalis [4]. Approximately 1 million women die from STI infections in Africa annually, 
and STIs are the second leading cause of loss of healthy life years for women aged 15-44 years [5]. 
Consequently, a growing concern. The three most common STIs, chlamydia, gonorrhoeae and 
syphilis, are increasingly proving difficult to treat, prompting the WHO to recently implement new 
guidelines [6]. 
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A study conducted in Kwazulu-Natal, South Africa, with a sample size of 5 748, reported a high STI 
prevalence rate of 13% with an incidence rate of 20 per 100 women years [1]. A comparative study 
conducted in South Africa (SA) and Zimbabwe reported the incidence rate of Neisseria gonorrhoeae 
to be higher in SA, accounting for 3.7 per 100 women years against 1.3 per 100 women years in 
Zimbabwe [4]. Consequently, an appreciable public health concern in South Africa. 
 
Primary health care (PHC) is the cornerstone of the public health system and essential health service 
delivery in SA [7]. This is in line with the requirements of the National Drug Policy (NDP) to provide 
access to quality, safe and affordable medicines to all citizens in SA [8]. The PHC system is based on 
the principles of scientific evidence for care, practicality in clinical settings, social acceptability and 
use of new technologies to guide health service provision [9]. These principles also apply to PHC 
facilities in correctional centres. This was highlighted in a recent speech where the National 
Commissioner for the Department of Correctional Services (DCS) highlighted that the DCS ensures 
that inmates are provided with access to PHC services in line with international and national 
protocols, guidelines and standards [10]. Currently, there are 243 correctional centres across SA, with 
only two being public/ private partnerships, with the DCS accredited by the Director General of Health 
to provide PHC facilities. Patients needing secondary or tertiary care are subsequently referred to 
appropriate Department of Health facilities.  
 
Standard Treatment Guidelines (STGs) are useful tools that can be used to guide decision making in 
health care provision. STGs reduce the variations in prescribed medicines, and guide prescribers on 
appropriate medicines for their patients, thereby improving the quality of health care provided [11, 12]. 
However, a recent study from Botswana showed that STGs were not always available in public PHC 
facilities impacting on the delivery of health care [12]. Although the availability of STGs alone cannot 
improve the appropriate use of medicines due to variable adherence rates, they are a good start [13-
16]. If STGs are not adhered to, patients may be prescribed incorrect treatments and sub-optimal 
doses as well as the incorrect duration of treatment [17]. This is particularly important for infectious 
diseases where incorrect treatment increases antimicrobial resistance (AMR) and the associated 
morbidity, mortality and costs [12, 13]. However, a study conducted by Gustafsson et al. (2011) 
among PHC facilities in Stockholm, Sweden, found high adherence rates to a recommended list of 
medicines (approximately 200) as well as treatment guidance at 80 ± 90% of prescriptions [18]. This 
was helped by evidence-based principles for developing treatment guidance and physician trust in 
colleagues developing the formularies [18, 19]. 
 
In SA, Standard Treatment Guidelines and the Essential Medicines Lists (STGs/EML) are available 
for ambulatory and hospital care of patients. In terms of the hospital level guideline, provision is made 
for both adults and children as treatments are not necessarily the same for these patients [20]. A list 
of tertiary and quaternary medicines for use in academic health institutions was also published in 
2012 [21]. Typically, SA uses the WHO guidelines in developing the criteria for selecting medicines for 
inclusion in the STGs/EML. Certain variables are assessed in order to ensure that the optimal 
medicine is included in the STGs/EML. These include scientific evidence of safety, efficacy, cost 
implications and, most importantly, public health relevance [22]. At PHC facilities flowcharts 
(algorithms), which are available in the PHC STGs/EML, are also used to guide health workers on the 
optimal management of health conditions [23]. 
 
The management of STIs requires that a proper diagnosis is made to facilitate appropriate treatment 
[2]. This necessitates immediate identification and treatment as soon as SRVVLEOHIRUWKHSDWLHQW¶V
immediate relief and, most importantly, to prevent the spread of infection. This is particularly important 
for patients with STIs with concomitant HIV [17]. The approach requires identification and prompt 
treatment of a group of signs and symptoms most commonly found in STIs, including the pathogens 
responsible for the given STI syndromes [24]. The success of STI management further requires that 
all sexual partners of patients presenting with STIs be identified in a timely fashion and treated 
properly. Reducing the period of infection is also important if the goal of adequate control of STIs, 
which is to prevent the increase in STIs, is to be achieved [17]. 
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However, among PHC facilities in developing and transitional countries there is generally suboptimal 
or poor compliance to prescribing guidelines and practices. Treatment prescribed according to STGs 
was only 40% in public facilities and less than 30% among private facilities across countries [25].  
 
Whilst it is possible to extrapolate the findings of studies conducted globally on the management of 
STIs to gain an understanding of the situation among PHC facilities in correctional centres, this 
approach is not ideal. The reason being a greater prevalence of STIs in correctional centres because 
of current practices compared to the general population, hence the findings might be different [7]. 
However, undocumented reports indicate low compliance levels with STGs/EML in correctional centre 
PHC facilities in the management of medical conditions necessitating further investigation.  
 
Consequently, we sought to determine the current level of compliance with the 2008 PHC STGs/EML 
in the management of STI syndromes among correctional centre PHC facilities in SA, as well as 
potential factors contributing to compliance and non-compliance with STGs/EML. As a result, future 
initiatives to improve compliance to STGs/ EML will be recommended. Additionally, the results of the 
study can be used as a baseline for undertaking future studies among PHC facilities in SA looking at 
compliance to optimise the future management of patients with infectious diseases including STIs. 
 
2. Patients and Methods 
 
2.1 Study setting and design 
An investigational descriptive study, including retrospective and prospective data, was conducted at 
two correctional centres in the North West Province of SA. One centre is a male only facility with a 
capacity of approximately 1 500 inmates, while the other centre, with a capacity of approximately 1 
400, houses both male and female inmates as well as awaiting trial detainees. Consequently, 
providing a broad population base representational of correctional centres in South Africa when 
combined. Both correctional centres have PHC facilities, providing comprehensive PHC services for 
the management of sick inmates with referral to external public sector facilities of the Department of 
Health for secondary and tertiary health care.  
 
We started with correctional centres as they are likely to have a higher prevalence of STIs than the 
normal population in view of current practices [26]. As a result, if there are issues with current STI 
management, these would be highlighted in this study. The findings of this study can form the basis of 
future studies among PHC facilities across SA.  
 
2.2 Data collection 
The Medicine Accounting Registers (MAR) were used to identify STI prescriptions for data collection. 
The MAR is used by prescribers to document the medicines issued to patients during consultations, 
GDWHRIFRQVXOWDWLRQDVZHOODVWKHSDWLHQWV¶XQLTXHUHJLVWUDWLRQQXPEHU. STI medicines, as outlined in 
the 2008 PHC STGs/EML, were identified in the MAR and used to select the relevant STI files. The 
determination of whether a specific STI is a new infection or recurrence was undertaken by the main 
researcher (TBM) upon checking all previous prescriptions for the same patient. The data were 
collected over a period of eight months (October 2014 to March 2015). Prescriptions for STIs were 
retrospectively reviewed to determine the level of compliance with the 2008 PHC STGs/EML. Only 
STI prescriptions written between January 2013 and March 2015 were considered for the study. This 
process was followed until a sample size of 385 was reached. Sample size estimation was 
undertaken using nQuery Advisor Release 7.0. With a sample size of 385 STI prescriptions, a two 
sided 95% confidence interval for the true (unknown) percentage of compliant prescriptions, will be 
within ±5% of the percentage that will be calculated from the sample, assuming a 50% compliance 
rate (which we believed was the worst scenario).  
 
Medicines were recorded by the INN (international non-proprietary name) in line with guidance to 
PHCs as medicines are procured by the Department of Health by their INN name. 
 
Face-to-face interviews were conducted by the principal researcher (TBM) initially targeting all 
authorised prescribers at the two correctional centres using a standard questionnaire (see Appendix 
1). The questionnaire was derived by the researchers based on their experience with and previous 
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research using semi-structured interviews to determine the various factors leading to either 
compliance with, or deviation from the 2008 PHC STGs/EML in the treatment of STIs [27]. The 
questionnaire was piloted for feasibility, and amended prior to the full study being conducted. 
 
In SA, prescribing is regulated in terms of the Medicines and Related Substances Control Act (101 of 
1965). All 13 prescribers were approached. However, four declined to be interviewed and one had 
resigned from one of the facilities before data collection, leaving eight to be interviewed. Out of the 
eight interviewed prescribers, one was a medical practitioner and seven were PHC trained nurses. 
Five of the authorised prescribers ZHUHPDOHDQGDOOHLJKWKDGPRUHWKDQ\HDUV¶H[SHULHQFH6L[
prescribers were above the age of 40. One of the nurse prescribers had a Bachelor of Nursing 
Science qualification while the others had a Diploma in Nursing.  
 
2.3 Data analysis 
Data were entered on Microsoft Excel® spreadsheets, verified for correctness and analysed 
descriptively using SAS® Release 9.2. Frequency percentages were used to summarise categorical 
variables. The prevalence of the different STIs treated at the centres was determined, followed by the 
frequency of the different antibiotics prescribed. Thereafter, the appropriateness of the prescribed 
antibiotic treatment was evaluated against the PHC STGs/EML [22]. A prescription was deemed fully 
compliant to the guidelines, if the combination of drugs prescribed for the particular STI, the dosages, 
the dosage interval and the duration of treatment were correct when compared with the treatment as 
outlined in the 2008 PHC STGs/EML. For the purpose of this study, all the aspects i.e. name of the 
medicine, dosage, dosage interval and duration of treatment, were given equal weight because they 
are seen to be equally important to treat identified STIs and data on how these should be weighted 
differently could not be found in the literature.  
 
Microsoft Excel® was used for a thematic analysis of the responses from the prescriber interviews to 
allow for narrative description and counting of responses within categories where possible.   
 
2.4 Ethical considerations 
Ethical clearance for the study was granted by the Medunsa Research Ethics Committee of the 
University of Limpopo (now Sefako Makgatho Health Sciences University) (MREC/H/25/2014.PG).  
Permission to conduct the study was granted by the Research and Ethics Committee at the 
Department of Correctional Services before commencement of the study. The study sites were 
informed of the study in writing and written informed consent was obtained from all interviewees. No 
personal information was recorded and all data were treated with the strictest confidentiality.  
Data collection sheets will be kept in a safe place for a period of five years, with access to the 
principal author only (TBM). 
 
3. Results  
 
3.1 Prescriptions for STIs 
The final sample included 357 prescriptions. Twenty eight (7.3%) of the 385 initially sampled 
prescriptions were not evaluable. The diagnosis indicated on these prescriptions did not match the 
STIs specified in the 2008 PHC STGs/EML and could therefore not be evaluated in terms of 
compliance with the 2008 PHC STGs/EML.  
 
3.2 Sexually transmitted infections (STIs) treated 
The frequency of the different STIs treated is summarised in Figure 1. From the 357 analysed 
prescriptions, the most common STI was male urethritis syndrome (MUS) which accounted for 170 
(47.6%) of the prescriptions, followed by lower abdominal pain (79; 22.1%) and genital ulcer 
syndrome (GUS) (67; 18.8%). The STI which occurred least often was balanitis (2; 0.6%).  
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Figure 1: Frequency (%) of different STI syndromes treated at the two correctional centres (n=357) 
 
 
 
 
Based on the 357 prescriptions analysed, a total number of 804 medicines were prescribed, which 
indicated an average of 2.28 medicines prescribed per prescription.  
 
Figure 2 shows the different antibiotics prescribed for the treatment of STIs within the 357 
prescriptions. A third of all prescriptions contained doxycycline (278; 32.5%), followed by ciprofloxacin 
(212; 24.8%) and metronidazole (111; 12.9%). Other antibiotics prescribed were cloxacillin and 
flucloxacillin although these are not recommended to treat any of the STIs; consequently, these were 
not analysed further.  
 
Further analysis of prescribed antibiotics indicated that a majority were in the therapeutic category 
tetracyclines (36.6%) followed by fluoroquinolones (26.6%) and nitroimidazoles (14.6). The least 
prescribed category was macrolides, which made up of only 1.2% of antibiotics prescribed (Table 1).  
 
  
47.6
22.1
18.8
4.5
2.8
1.4
1.1
1.1
0.6
Male urethritis syndrome
Lower abdominal pain
Genital ulcer syndrome
Vaginal discharge
syndrome
Male urethritis syndrome-
Genital ulcer syndrome
Genital warts
Bubo
Scrotal swelling
Balanitis
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Table 1: Percentage utilisation of antibiotics versus all medicines prescribed and broken down by ATC 
class  
 
Medicine Antibiotic 
classification 
 ATC code Number  of 
antibiotics 
within the total 
medicines 
prescribed* 
% of antibiotics 
prescribed 
against total 
antibiotic usage 
(n=759) by ATC 
class 
Azithromycin Macrolides  J01FA 9 (1.1%) 1.2% 
Ceftriaxone  Cephalosporin  J01DB/C 14 (1.6%) 1.8% 
Penicillin G Penicillins  J01CA 24 (2.8%) 3.2% 
Erythromycin  macrolides J01FA 26 (3.0%) 3.4% 
Cefixime  Cephalosporins  J01DB/C 85 (9.9%) 11.2% 
Metronidazole  Nitroimidazoles  P01AB 111 (12.9%) 14.6% 
Ciprofloxacin  Fluoroquinolone  J01MA 202 (24.8%) 26.6% 
Doxycycline  Tetracycline  J01AA 278 (32.5%) 36.6% 
NB. % = % of prescriptions (n=357) containing the designated antibiotic 
 
Additional to antibiotics, other medicines prescribed included paracetamol (19; 2.4%), ibuprofen (17; 
2.1%) and other medicines (15; 1.9%) such as potassium citrate mixture, chlorpheniramine and 
vitamin B complex. Acyclovir (26; 3.2%) was the only antiviral prescribed and clotrimazole (16; 2.0%) 
was the only antifungal prescribed. Table 2 provides recommendations on the suggested treatment 
approaches to STIs as stipulated in the 2008 STG/ EML [22]. 
 
Table 2: Sexually transmitted infections and the management thereof as stipulated by the PHC 
STGs/EML 
 
Condition Treatment  
MUS Cefixime, oral, 400mg as a single dose and doxycycline, oral, 100mg 12 hourly for 7 
days 
SSW 
 
Ceftriaxone, IM, 250mg as a single dose and doxycycline, oral, 100mg 12 hourly for 
14 days 
GUS Benzathine benzylpenicillin, IM, 2.4MU single dose plus erythromycin, oral, 500mg 
6 hourly for 7 days plus acyclovir, oral 400mg 8 hourly for 7 days 
Bubo Doxycycline, oral, 100mg 12 hourly for 14 days and ciprofloxacin 500mg 12 hourly 
for 3 days 
Balanitis  Clotrimazole cream, applied 12 hourly for 7 days 
Syphilis Benzathine benzyl penicilin 2.4mu as a single dose 
GW Podophyllin solution 20% 
PL Benzyl benzoate 25% 
LAP Ceftriaxone, IM, 250mg single dose and doxycycline, oral, 100mg 12 hourly for 14 
days and metronidazole, oral, 400mg 12 hourly for 14 days 
VDS Cefixime, oral, 400mg as a single dose and doxycycline, oral, 100mg 12 hourly for 7 
days and metronidazole, oral, 2g as a single dose 
MC Iodine tincture 
Source: 2008 PHC STGs/EML [22]  
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Figure 2: Antibiotics prescribed for STIs  
 
 
NB. % = % of 357 prescriptions containing the designated antibiotic 
 
3.3 Compliance of individual drugs with the 2008 PHC STGs/EML 
Each individual medicine prescribed for the treatment of the specific STI indicated by the diagnosis, 
was evaluated for compliance with the 2008 PHC STGs/EML (Table 2). This was undertaken by 
determining whether the medicine, the dosage, the dosage interval and the duration of treatment were 
compliant with the recommendations (see Table 3). 
 
Doxycycline, the most commonly prescribed antibiotic, was prescribed as an individual item according 
to the 2008 guideline in 95.0% of the prescriptions, ciprofloxacin in 90.6% of prescriptions, 
metronidazole in 90.1% of prescriptions and cefixime in 82.4% of prescriptions (Table 3). Other 
medicines included acyclovir with 25 out of the 26 prescriptions being compliant with the treatment in 
the 2008 guideline, clotrimazole with 14 out of the 16 being compliant and podophyllin being 
compliant in all 3 prescriptions for genital warts. 
 
In 688 (80.5%) of the medicines prescribed, the dosage was compliant with the 2008 guideline, the 
dosage for 82 (9.6%) drugs was non-compliant and for 34 (3.9%) medicines, no dosage was indicated 
(Table 3).  
 
The duration of treatment was compliant and non-compliant with the 2008 guidance in 346 (40.5%) 
and 110 (12.9%) of the prescriptions respectively, and was not indicated in 348 (40.7%) of the 
medicines prescribed. Lastly, the interval was compliant and non-compliant in 637 (74.5%) and 134 
(15.6%) of the medicines prescribed according to the 2008 guideline respectively. 
32.5%
24.8%
12.9%
9.9%
3.0%
2.8%
1.6%
1.1%
0% 5% 10% 15% 20% 25% 30% 35%
Doxycycline
Ciprofloxacin
Metronidazole
Cefixime
Erythromycin
Penicillin G
Ceftriaxone
Azithromycin
% of prescriptions
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Table 3: Compliance of individual drugs prescribed for the treatment of STI syndromes with the 2008 STGs/EML  
 
Antibiotic 
prescribed 
Drug Dosage Dosage interval Duration of treatment Overall 
compliance 
(combining 
all factors) Compliant 
Non-
compliant 
Compliant 
Non-
compliant 
No 
informatio
n 
Compliant 
Non-
compliant 
No 
information 
Compliant 
Non-
compliant 
No 
information 
Doxycycline 264 (95.0%) 14 (5.0%) 260 (93.5%) 15 (5.4%) 3 (1.1%) 252 (90.6%) 15 (5.4%) 11 (4.0%) 65 (23.4%) 16 (5.6%) 197 (70.9%) 60 (21.6%) 
Ciprofloxacin 192 (90.6%) 20 (9.4%) 188 (88.7%) 20 (9.4%) 4 (1.9%) 165 (77.9%) 45 (21.2%) 2 (1.0%) 124 (58.5%) 47 (22.2%) 41 (19.3%) 118 (55.7%) 
Metronidazole 100 (90.1%) 11 (9.9%) 88 (79.3%) 20 (18.0%) 3 (2.7%) 67 (60.4%) 42 (37.8%) 2 (18.0%) 35 (31.5%) 21 (18.9%) 55 (49.5%) 31 (27.9%) 
Cefixime 70 (82.4%) 15 (17.6%) 68 (80%) 15 (17.6%) 2 (1.8%) 68 (80%) 15 (13.5%) 2 (2.4%) 64 (75.3%) 15 (17.6%) 6 (7.1%) 62 (72.9%) 
Acyclovir 25 (96.2%) 1 (3.8%) 16 (61.5%) 1 (3.8%) 9 (34.6%) 20 (76.6%) 1 (3.8%) 5 (1.9%) 11 (42.3%) 1 (3.8%) 14 (53.8%) 10 (38.5%) 
Benzathine 
benzylpenicilli
n 22 (91.7%) 2 (8.3%) 22 (91.7%) 2 (8.3%) 0 20 (83.3%) 2 (8.3%) 2 (8.3%) 20 (83.3%) 2 (8.3%) 2 (8.3%) 15 (62.5%) 
Erythromycin 21 (80.8%) 5 (19.2%) 21 (80.8%) 5 (19.2%) 0 19 (73.1%) 5 (19.2%) 2 (7.7%) 5 (19.2%) 5 (19.2%) 16 (61.5%) 3 (11.5%) 
Clotrimazole 14 (87.5%) 2 (12.5%) 6 (37.5%) 3 (18.8%) 7 (43.8%) 4 (25.0%) 8 (50.0%) 4 (25.0%) 1 (6.3%) 2 (12.5%) 13 (81.3%) 1 (6.3%) 
Ceftriaxone  13 (92.9%) 1 (7.1%) 10 (71.4%) 1 (7.1%) 3 (21.4%) 13 (92.6%) 1 (7.1%) 0 13 (92.6%) 1 (7.1%) 0 7 (50.0%) 
Azithromycin 9 (100.0%) 0 9 (100.0%) 0 0 9 (100.0%) 0 0 8 (88.9%) 0 1 (11.1%) 8 (88.9%) 
Podophyllin 3 (100.0%) 0 0 0 3 (100.0%) 0 0 3 (100.0%) 0 0 3 (100.0%) 0 
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3.4 Compliance to the 2008 PHC STGs/EML for STI treatment 
Although individual antibiotics prescribed typically complied with the 2008 PHC STGs/EML (Table 3), 
compliance levels for combined treatment for specific STI diagnoses were variable (Figure 3). As 
mention, all aspects of compliance, i.e. the name of medicine, dosage, dosage interval and duration 
of treatment, have been equally weighted to arrive at a conclusion as to whether the prescription is 
compliant or not. 
 
Compliance with the 2008 PHC STGs/EML for MUS prescriptions was 75.9% (129 prescriptions, 95% 
confidence interval (CI) 68.9% - 81.7%), for lower abdominal pain (LAP) compliance was 11.4% (9 
prescriptions, 95% confidence interval (CI) 6.1% - 20.3)) and 14.9% (10 prescriptions, 95% 
confidence interval (CI) 8.3% - 25.3%) for genital ulcer syndrome (GUS). Confidence intervals for 
VDS, MUS-GUS, Bubo, Balanitis and Genital Warts were not documented as they were not reliable 
due to very small sample sizes. 
 
Figure 3: Percentage of prescriptions compliant to the 2008 PHC STGs/EML for the treatment of 
different STIs (n=357) 
 
 
NB:  Lower abdominal pain (LAP); vaginal discharge syndrome (VDS); genital ulcer syndrome (GUS); male 
urethritis syndrome (MUS) 
 
3.5 Compliance to the 2008 PHC STGs/EML for MUS prescriptions 
The 2008 PHC STGs/EML specifies cefixime and doxycycline as first line treatment for MUS with the 
addition of metronidazole for recurring cases of MUS infection. Ciprofloxacin is indicated in patients 
with a known allergy to cefixime. Table 4 documents current compliance rates to the 2008 PHC 
STGs/EML. 
 
  
75.9%
50.0%
40.0%
25.0%
20.0%
14.8%
12.5%
11.4%
24.1%
50.0%
60.0%
75.0%
80.0%
85.1%
87.5%
88.6%
100.0%
0% 20% 40% 60% 80% 100%
MUS (n=170)
Balanitis (n=2)
Genital Warts (n=5)
Bubo (n=4)
MUS-GUS (n=10)
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LAP (n=79)
Scrotal swelling (n=4)
% of prescriptions
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Table 4: Compliance with 2008 PHC STGs/EML of antibiotics prescribed for MUS (n=170) 
 
* Therapeutic alternative 
 
Table 4 shows that only 38 (22.4%) MUS prescriptions containing cefixime complied with the 2008 
PHC STGs/EML, signifying low compliance. However, assuming that all patients allergic to cefixime 
were prescribed ciprofloxacin, the compliance of MUS prescriptions increases to 129 (75.9%) 
combined with two prescriptions containing ceftriaxone, as a therapeutic alternative to cefixime. 
 
3.6 Compliance with the 2008 PHC STGs/EML for LAP prescriptions (n=79) 
The 2008 PHC STGs/EML outlines ceftriaxone, doxycycline, and metronidazole as first line treatment 
for LAP which is the second most common STI in the study and accounted for (79; 22.1%) of 
prescription. Patients allergic to penicillin might also react to cephalosporins such as ceftriaxone and 
should be treated with ciprofloxacin. Table 5 documents the prescribed antibiotics for LAP.  The 
analysis of the prescribed antibiotics shows that only 11.4% (9 prescriptions) of LAP prescriptions 
complied with the treatment as outlined in the 2008 PHC STG/EML signifying low compliance levels. 
 
  
Compliant Non-compliant 
Medicine 
First 
encounter 
Recurrent 
Medicine No (%) 
No (%) No (%) 
cefixime +  doxycycline 26 (15.3%)  doxycycline 2 (1.2%) 
cefixime + doxycycline + 
ibuprofen 1 (0.6%)  
doxycycline + 
metronidazole + 2 (1.2%) 
cefixime + doxycycline + 
potassium citrate mixture 1 (0.6%)  
doxycycline + 
metronidazole + 
paracetamol 1 (0.6%) 
cefixime + doxycycline + 
metronidazole 
 
 9 (5.3%) 
cefixime + 
metronidazole 1 (0.6%) 
cefixime + doxycycline + 
metronidazole + paracetamol  1 (0.6%) 
erythromycin + 
acyclovir topical 1 (0.6%) 
ceftriaxone +  doxycycline 2* (1.2%)  
azithromycin + 
ceftriaxone 
+metronidazole 2(1.2%) 
Sub-total 
30 (17.6%) 10 (5.9%) 
azithromycin + 
ceftriaxone + 
metronidazole 2 (1.2%) 40 (23.5%) 
Ciprofloxacin + doxycycline 78 (45.9%)  
Benzathine 
benzylpenicillin + 
erythromycin + 
paracetamol 2 (1.2%) 
Ciprofloxacin + doxycycline + 
metronidazole  11 (6.5%) 
Benzathine 
benzylpenicillin + 
erythromycin 1 (0.6%) 
Sub-total 
78 (45.9%) 11 (6.5%) 
Others 23 (13.5%) 89 (52.4%) 
Total 108 (63.5%) 21 (12.4%) Total 41 (24.1%) 
Grand total 129 (75.9%) 41 (24.1%) 
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Table 5:   Antibiotics prescribed for LAP (n=79) 
 
Medicine No  Medicine No 
Cefixime 1 Ciprofloxacin + Doxycycline + 
Metronidazole 
6 
Cefixime + Doxycycline + 
Metronidazole 
15 Ciprofloxacin + Ibuprofen    
 
 
6 
Ceftriaxone + Doxycycline    2 Ciprofloxacin + Metronidazole  4 
Cefixime + Doxycycline + 
Metronidazole + Mist Pot Cit    
1 Ciprofloxacin + Mist Pot Cit 1 
Ciprofloxacin 12 Ciprofloxacin + Paracetamol   5 
Ciprofloxacin + Clotrimazole + 
Doxycycline +                        
Metronidazole    
1 Ciprofloxacin + Vitamin B Co  1 
Ciprofloxacin + Doxycycline    8 Doxycycline  1 
 
*Ciprofloxacin + Doxycycline + 
Metronidazole 
9 
(11.4%) 
Flucloxacillin +Metronidazole  1 
Ciprofloxacin + Erythromycin 1 Erythromycin + Metronidazole  4 
 
 
3.7 Compliance to the 2008 PHC STGs/EML for GUS prescriptions 
 
For GUS, the third most common STI, accounting for (67; 18.8%) of all STI prescriptions, Benzathine 
benzylpenicillin, erythromycin, plus acyclovir are recommended as first line treatment in the 2008 
PHC STGs/EML. From the total of 29 different antibiotic combinations, only 14.9% (10 prescriptions) 
were compliant with the treatment as indicated in the 2008 PHC STG/EML. 
 
3.8 Perceptions of prescribers on factors contributing to compliance with, or deviations from 
the 2008 STGs/EML 
 
3.8.1 Responses by prescribers on the use of the 2008 PHC STGs/EML  
All eight prescribers interviewed indicated that they used the 2008 PHC STGs/EML when treating 
STIs. Six prescribers¶UHDVRQIRUusing the 2008 guidance when treating STIs was because it was a 
national guideline, two indicated that they use it because there was no alternative and the guideline 
contained the treatment they use for different diseases. Only one prescriber indicated that it was the 
most cost-effective way to treat STIs. 
 
Although only one of the prescribers indicated the cost-effectiveness of using the 2008 guidance in 
treating STIs, when a direct question was posed to all prescribers as to whether they thought the 
guidelines was the most cost-effective way to treat STIs, they all agreed with this statement.  
 
The prescribers further provided the following reasons as to why they thought that the guidelines were 
cost-effective: 
x Most of the treatments are available 
x General measures such as health education are also included 
x Most of the medicines in the 2008 PHC guidance are not costly and actually do work 
x Proper management that prevents additional costs associated with referrals 
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x Standard treatment for more common conditions and therefore only needed to keep required 
stock 
x Treatment always has positive outcomes 
x Medicines are well researched by experts 
 
Although prescribers indicated that they use the 2008 PHC STGs/EML when treating STIs, two 
prescribers specified that there are instances where they are unable to fully utilise it such as when 
certain medicines used to treat STIs are not available. 
 
3.8.2 Induction on the use of the 2008 PHC STGs/EML 
Five prescribers reported that they were inducted on the use of the 2008 PHC STGs/EML and that the 
induction was useful, while three of the prescribers reported that they were not inducted. One out of 
the five prescribers indicated that the induction took place in 2008 when the 2008 PHC STGs/EML 
was launched while the rest reported that their induction took place only at a later stage after the 2008 
PHC STGs/EML was launched, i.e. between 2009 and 2011. 
  
Specific reasons provided as to why they thought the induction was useful included the following:  
x Provided guidance on how STI and HIV contacts can be traced and assisted with counselling and 
how to better manage STIs and HIV   
x Enabled one to do a proper diagnosis and choose the correct treatment 
x Explained the details and the step by step management  
x New information was included and had to be implemented  
x Theory was translated to practice, build intelligence and assist in reaching the goal of clinical care 
 
3.8.3 Performance of self-audits 
When the eight interviewed prescribers were asked whether they performed self-audits to check if 
they complied with the 2008 PHC STGs/EML when managing STIs, four prescribers indicated that 
they do not, while the other four confirmed that they do perform self-audits.  
 
The reasons provided by those who performed self-audits as to why and how they do the audits, 
included the following: 
x During consultation with the patients there is no time to look at the guidelines and performing self-
audits later on provides information on whether the correct treatment was issued to the patient 
x To verify if the correct treatment was provided during consultation with the patient  
x Use own knowledge when consulting patients and only refer to the 2008 PHC STGs/EML when 
there is a need to double check 
x To check how many patients were treated according to the 2008 PHC STGs/EML 
 
The reasons provided by those who did not perform self-audits included limited time and shortage of 
staff, which makes it impossible to perform the audits. The sessional medical practitioner indicated 
that there is no time, as they are only at the facility two days per week, for a maximum of two hours 
per day. 
 
3.8.4 Compliance to the 2008 PHC STGs/EML as part of performance evaluation 
Five prescribers mentioned that compliance to the 2008 guidance forms part of their performance 
evaluation and this encouraged them to use the guidelines, while three said it did not form part of their 
performance evaluation. 
 
3.8.5 Training in effective prescribing and rational medicines use 
The medical practitioner was the only prescriber who reported to have been trained in effective 
prescribing and rational medicines use. This was despite five prescribers indicating that they have 
been inducted in the use of the 2008 PHC STGs/EML, which could be viewed as training on rational 
medicines use. 
 
3.9 Concomitance of HIV and how it affects the diagnosis and treatment of STIs 
The prescribers were further asked if they thought diagnosing STIs in patients with concomitant HIV 
infection was difficult or not. Although they indicated that concomitant HIV infection does not affect the 
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ease of diagnosing STIs, they also believed that cases are different and they provided the following 
reasons: 
x Certain patients in correctional centres do not provide accurate information or they do not disclose 
all the information, making it difficult for proper diagnosis 
x Some HIV positive patients present with opportunistic infections which can be misdiagnosed as 
STIs 
x STIs present differently in males and females 
x STIs are complicated in immunocompromised patients 
x Additional medicines might be required in patients having other HIV related opportunistic 
infections 
x Patients that are non-compliant with their antiretroviral treatment do not respond well to STI 
treatment requiring additional medicines to be added 
 
4. Discussion 
 
The results showed generally low compliance levels with the 2008 guidelines in the management of 
STIs among correctional facilities in SA. However, this was variable (Figure 2). Compliance levels 
were 14.8% for GUS, 12.5% for VDS and 11.4% for LAP; however 75.9% for MUS (Table 4,5; Figure 
2). These findings are similar to those of Igbojiaku et al. (2013) in a regional hospital in Kwazulu-Natal 
where low compliance levels with diabetic guidelines was reported [28]. Another study conducted in 
Kwazulu-Natal found only 38% of prescriptions were compliant with the guidelines [27]. However, 
different to the findings of Sooruth et al. where professional nurses working in PHCs in Kwazulu-Natal 
appeared to be prescribing rationally according to the 2008 STG/ EML; although, concerns with 
scheduling and administration of medicines [29]. 
 
However, there were typically higher compliance levels with the 2008 PHC STGs/EML when 
assessing individual antibiotics when managing specific STIs (Table 3). Azithromycin was prescribed 
according to the 2008 PHC STGs/EML in 100% of the prescriptions, doxycycline in 95%, followed by 
ceftriaxone with 92.9% and erythromycin in 80.8% of prescriptions. These findings are contrary to 
those of Wang et al. (2014) reporting on antibiotics prescribed in Chinese PHC facilities  [30], which is 
encouraging. 
 
There were concerns with the duration of treatment in our study, where in 40.5% of occasions  this 
was inappropriate (Table 2). However, the interval was compliant in 74.5% and the dosage compliant 
in 80.5% of antibiotics prescribed respectively. This shows  that although the appropriate antibiotic 
was prescribed, prescribers sometimes failed to prescribe the appropriate duration, interval and 
dosage.  
 
Even though the prescription analysis showed compliance to the 2008 PHC STGs/EML was typically 
low, prescribers stated in the interviews that they utilised the guideline when managing STIs (Section 
3.8.1). This reflects findings among PHC facilities in Botswana where STI STGs were generally 
available compared with STGs and documents for other disease areas [12]. Prescribers further stated 
that they have been inducted on the use of the guidelines, and this was useful (Section 3.8.2), 
compliance formed part of their performance evaluation and that regular self-assessments were 
conducted. However, differences between beliefs and the current situation needs to be investigated 
further to reduce the threat of AMR [6]. This is because whilst the eight prescribers interviewed 
indicated they had received training on the utilisation of the 2008 PHC STGs/EML, and that the 
training was useful (Section 3.6), this was only conducted later after the implementation of the 2008 
PHC STGs/EML and this might have contributed to their low compliance levels. 
 
 
Two barriers appeared to negatively impact on compliance with the 2008 PHC STGs/EML. These 
included the non-availability (shortage) of certain STI medicines and the fact that some of the STI 
medicines were not kept as clinic stock. This is similar to the findings of Engelbrecht (2010) [31] and y 
Mash et al. [7]. In addition, according to Engelbrecht [31], lack of training on the importance of and 
implementation of guidelines also contributes to their non-compliance. 
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4.1 Limitations 
 
We recognise that a major limitation of this study is that it was only conducted in two correctional 
centre PHC facilities. Furthermore, sampling STI prescriptions utilising medicines in the MAR might 
have led to some prescriptions being missed if these were not recorded in the MAR. In addition, 
patient factors such as allergy status were not always recorded.  We are also aware that the 2008 
PHC STGs/EML was reviewed and the 2014 edition was published in 2015 after data collection was 
complete.  The new edition makes reference to the inclusion of the level of evidence and practice 
implications as decision-making criteria for inclusion of medicines in the guidelines. These changes 
however did not have any meaningful impact on the findings of this study. 
 
Consequently, we believe our findings are robust in view of the characteristics of the correctional 
centres chosen. In addition, the differences between the findings from the treatment charts and 
prescriber feedback are worth future investigation. Consequently, further research will be conducted 
across the country in different PHC facilities to further assess compliance with STGs/EML when 
treating infectious diseases such as STIs to develop additional recommendations to enhance the 
management of patients with STIs across SA, thereby reducing AMR rates. These will build on the 
recommendations that can already be made following this research. 
 
4.2 Recommendations 
 
In order to improve compliance with the PHC STGs/EML, we believe it is important that health 
professionals, especially clinical nurse practitioners are inducted on the use of STGs/EML as soon as 
possible after their finalisation and publication. This sentiment has been echoed by the National 
Commissioner of DCS when he highlighted the need to provide health care workers with the 
necessary training to enable them to execute their duties appropriately [10]. We believe regular 
refresher training courses should also be conducted to ensure prescribers are continuously sensitized 
on using the PHC STGs/EML. This is especially important in the PHC model that places clinical nurse 
practitioners at the centre of health provision [29], similar to other countries [13]. 
 
We also believe in view of our findings that communication between prescribers and pharmacists 
must be strengthened so that its clear which STIs are being treated so that the appropriate 
recommended medicines are readily available. To address stock outs, pharmacists and pharmacy 
support personnel should undergo regular refresher training on medicine supply management. 
In addition, we believe the introduction of a managerial monitoring tool to assess future prescribing 
patterns should also be implemented. The findings should be utilised by operational and regional 
managers to further improve future prescribing. This has worked well in other countries [18, 19]. 
 
Pharmacists can also play a leading role in promoting the use of STGs/EML in PHC facilities, 
conducting drug utilisation reviews and using the findings to stimulate discussions to further enhance 
the rational use of medicines among PHC facilities in SA.  Antimicrobial stewardship programmes can 
also be implemented across sectors in order to improve antibiotic prescribing, monitor antimicrobial 
usage and implement interventions to optimise antimicrobial use to reduce antibiotic resistance. 
Pharmacists and other healthcare professionals can play a leading role in this. The success of these 
interventions in improving compliance rates has been seen in countries [18, 19].  
 
Key points 
 
x Globally, sexually transmitted diseases are among the most common acute conditions with 
significant public health concerns, with STIs being the second leading cause of health life years 
among women aged 15 ± 44 years in Africa 
 
x Consequently, correct treatment is important especially as sub-optimal treatment will increase 
antimicrobial resistance. This is particularly important in Primary Health Care centres in Africa 
including South Africa, especially correctional centres with a greater prevalence of STIs  
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x Male urethritis syndrome, lower abdominal pain and genital ulcer syndrome were the three most 
common STIs found among inmates in correctional centres in SA, with doxycycline, ciprofloxacin 
and metronidazole the most prescribed antibiotics 
 
x Overall compliance to the 2008 PHC STGs/EML was low for the STIs, although doses were 
compliant in over 80% of prescriptions. There is a need to improve this through educational and 
other activities 
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Appendix 
Appendix 1 - Compliance to the Primary Health Care Treatment Guidelines and Essential 
Medicines List in the Management of Sexually Transmitted Infections  
Date: ____________________ 
TICK (¥) THE APPROPRIATE BOX BELOW 
Qualification:                                                                                                         Gender:      
 
 
 
                                                      Age: 
 
Years of experience: 
 
 
 
 
 
1. Do you use the 2008 PHC STGs/EML in the treatment of STIs in the clinic?  
              >3OHDVHWLFN¥WKHFRUUHFWDQVZHU@ 
              If yes, can you please explain why? 
««««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
If not, please explain why you are not using it? 
««««««««««««««««««««««««««««««««««««««««««««««
«««««««««««««««««««««««««««««««««««««««««««««« 
2. Were you ever inducted on the use of the 2008 PHC STGs/EML?  
             >3OHDVHWLFN¥WKHFRUUHFWDQVZHU@ 
 
If yes, please indicate when you were inducted. 
«««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
Male Female 
  
MBCHB  
B Curr  
Other    20 
years 
21-30 
years 
31-40 
years 
40 
years 
    熟1 year 1-5 years 5-10 years 出10 years 
    
Yes  No  
Yes  No  
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Was the induction useful? 
 
   >3OHDVHWLFN¥WKHFRUUHFWDQVZHU@ 
Please motivate your answer. 
«««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
 
If no, would you be interested in attending such training?  
   >3OHDVHWLFN¥WKHFRUUHFWDQVZHU@ 
Please motivate your answer. 
«««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
 
3. Which other guidelines are you using for the management of STIs in the clinic?  
«««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
In what way do these guidelines differ from the 2008 PHC STGs/EML, please explain your answer? 
«««««««««««««««««««««««««««««««««««««««««««««
««««««««««««««««««««««««««««««««««««««««««««« 
4. Do you think the 2008 PHC STGs/EML is the most cost-effective way to treat STIs? 
   >3OHDVHWLFN¥WKHFRUUHFWDQVZHU@ 
 
Please motivate why you think so. 
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